ABPI scolds Novo on Victoza promos; Jeffries downgrades BMS;

@FiercePharma: J&J splits off troubled consumer-drug unit. Article  | Follow @FiercePharma

> Novo Nordisk management was cited by the Association of the British Pharmaceutical Industry for breaching industry codes concerning various promotional efforts for its Victoza diabetes med. Story

> Bristol-Myers Squibb received some good news last week with the approval of its cancer treatment Yervoy, but at least one analyst believes the drugmaker now faces pressures that spare little room for near-term earnings momentum. Item

> Takeda Pharmaceutical tapped Trevor Smith to lead its Takeda Pharmaceuticals Europe subsidiary as CEO; Smith currently is VP of international strategy. News

> Several dozen people protested around London over Johnson & Johnson's ongoing refusal to participate in the Medicines Patent Pool, an initiative designed to broaden access to HIV meds in developing countries. News

> Boehringer Ingelheim got the FDA nod for its extended-release version of the HIV-fighting drug Viramune. Story

> Watson Pharmaceuticals is launching Nulecit, the first copycat version of the Sanofi-Aventis anemia drug Ferrlecit. Report

> Joann Eisenhart, who most recently was senior vice president of human resources at Pfizer, has been named vice president of human resources of Northwestern Mutual. Article

Biotech News

 @FierceBiotech: Valeant vows to restructure Cephalon as it moves in for the kill. Report | Follow @FierceBiotech 

 @JohnCFierce: Andrew Polllack on the ups and downs of developing radiation exposure drugs for the government. Report| Follow @JohnCFierce 

> Pfizer R&D chief: Less R&D spending is better. News

> Report: Antibiotic pipeline woefully thin. Item

> Omeros hit hart on knee surgery drug failure. Article

And Finally... A significant portion of people--perhaps as many as one in five--don't take drugs a doctor has prescribed because they can't pay for them, according to a new survey of people visiting an emergency room. Report

Suggested Articles

With tens of millions of Americans tuned into Tuesday’s presidential debate, the race for a COVID-19 vaccine took center stage in a big way.

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi